Thank you. Good afternoon, everyone, and thank you for joining us. I am Hilde Steineger, CEO of Cantargia. Today I will present our Q1 2026 update and progress across all our IL1RAP platform, including how we are adapting our Oncology strategy to an evolving treatment landscape.
Next slide please. Before we begin, I'd like to address forward-looking statements.
This reflects our current expectations and involves risks and uncertainties that could cause actual outcomes to differ materially. I'd ask everyone to read this statement carefully and keep it in mind throughout the presentation.
Next slide please. I'm joined today by Patrik Renblad, our Chief Financial Officer. Together, we'll take you through the developments in the last quarter. We'll start with the strategic perspectives, then move through the portfolio clinical updates and key financials.
Next slide please. Today I will outline how we are refining our development focus across the company's core value drivers. In PDAC. Recent clinical advances have increased focus on this disease area, and the treatment landscape is evolving quickly, with RAS inhibitors poised to become an important part of future care. Against that backdrop, we see a clear opportunity for Nadunolimab in combination settings, and we are refining the design and timing of our planned Phase 2b/3 study to better position the program in this emerging landscape. In Hematology, we see early and encouraging signals from the MD Anderson study in MDS, supported by a strong scientific rationale for IL1RAP in hematologic malignancies. Beyond this, we are maintaining a long-term pipeline perspective, including our next-generation bispecific work in inflammation, building on the biology behind CAN14. Finally, Wolfram Dempke will transition from the role of Chief Medical Officer to continue to support Cantargia as chair of our PDAC Scientific Advisory Board, thereby ensuring continuity as we align the organization with the next phase of development. Next slide. This slide provides an overview of the pipeline built around IL1RAP in Oncology. Nadunolimab remains a significant value driver with continued opportunity in PDAC, supported by regulatory designation, including Fast Track and Orphan Drug status by the FDA. At the same time, the program has gained further momentum from encouraging new data in the investigator-initiated MDS/AML study at MD Anderson, which adds an important second clinical opportunity for Nadunolimab. Beyond the lead program, Cantargia continues to advance a broader discovery engine for the next generation IL-1 based therapies. Together, these activities reflect the breadth of the platform, with multiple clinical and preclinical opportunities built around the biologically validated target.
Next slide. Hail. High IL1RAP expression is linked to poor outcome in patients with pancreatic tumor, as shown before. And we have shown together with other groups that IL1RAP is a clear prognostic marker in PDAC, high IL1RAP marks a more aggressive and harder to treat form of disease.
Taken together, these findings reinforce the relevance of IL-1RAP in PDAC, particularly in patients with the greatest unmet need. Next slide, please. Moving, then, from biological rationale to clinical relevance. Patients with high IL1RAP expression treated with Nadunolimab in combination with Gemcitabine showed a clearly stronger overall survival signal than the low expression group. Median overall survival was 14.2 months versus 10.6 months with statistical significance. We also saw strong 12- and 24-month overall survival rates in the IL-1 Rap high group. Together, this suggests that IL1RAP expression may help to identify the patients where Nadunolimab has the greatest potential clinical impact. Our confidence in Nadunolimab's future role in PDAC is grounded in the biology.
KRAS and IL1RAP appear to act in concert, shaping both tumor biology and the inflammatory tumor microenvironment. This provides a strong rationale for combination strategies, particularly as RAS inhibitors become a more important part of future PDAC treatment. Importantly, IL1RAP remains relevant in both KRAS mutant and non-mutant settings, supported by broad applicability. These findings suggest that opportunity extends beyond a single pathway and supports Nadunolimab as a potential relevant combination partner in a broader PDAC treatment landscape.
Pdac remains one of the most lethal solid tumors, and survival in advanced disease is still measured in months despite incremental treatment progress.
First-line standard of care continues to rely on chemotherapy, with limited improvement in overall outcomes. At the same time, the field is rapidly evolving, particularly in the context of emerging therapies. As mentioned, the emergence of RAS inhibitors, bringing greater attention and renewed hope for PDAC patients. These agents have the potential to become an important component of future treatment, while also creating new opportunities for differentiated combination partners.
Next slide. So, Nadunolimab is positioned to fit into this changing PDAC treatment environment in several complementary ways.
As standard of care shifts toward more targeted and biomarker-driven approaches, its profile could allow us to integrate it into different combination strategies rather than being tied to a single regimen or line of therapy. With this slide. What this slide highlights is the development flexibility that Nadunolimab may offer in PDAC. It may have a role with chemotherapy, alongside RAS-targeted therapy, or in combination strategies that reflect how the standard of care evolves from a strategic perspective. It broadens the path available for Nadunolimab development in PDAC and supports relevance across multiple future treatment settings.
Next slide please. This next step reflects the strategy. In practice, we are preparing a Phase 1b study of Nadunolimab in combination with most likely Daraxonrasib in PDAC patients whose disease has progressed after first-line standard of care. The initial objective is to establish safety and tolerability, while also exploring early signs of efficacy and relevant inflammatory and immune biomarkers. Timing is currently expected to start in Q4 2026 into the Q1 2027 period, subject to funding, regulatory approval, and drug availability.
Strategically, this study is important because it expands Cantargia PDAC opportunity beyond current chemotherapy-based combinations and helps position Nadunolimab within a more biomarker-driven and targeted treatment landscape.
Next slide. Now, turning to the Hematology rationale. Next slide please. Thank you. The rationale for IL1RAP in MDS and AML is grounded in core disease biology in both settings. IL1RAP is associated with leukemic stem cells, placing it close to mechanisms of disease, persistence, and progression. From the patient's perspective, that matters because higher risk MDS still carries a substantial risk of progressing to AML. While the durability of current treatment remains limited for many patients. In AML, outcomes also remain challenging despite targeted advances. Taken together, AML and MDS remain an area with high unmet need where a target like IL1RAP, positioned close to core disease mechanisms, may have particular clinical relevance.
Next slide. In high-risk MDS.
The opportunity is supported by both significant patient need and a meaningful market backdrop. The disease affects a substantial global patient population. Outcomes are particularly poor in key subgroups, and many patients are not eligible for potentially curative transplant.
Hypomethylating agents remain the treatment backbone, but response rates and durability still leave a large gap, especially after treatment failure.
In that context, the indication combines clear medical need with attractive market characteristics, which could make it a strategically important product or clinical indication for Cantargia over time.
Next slide. Leukemic stem cells are thought to contribute to relapse and treatment resistance, making them important therapeutic targets.
IL1RAP is expressed on these cells in AML and high-risk MDS, while being much less relevant in normal hematopoietic stem cells, which provides a biologically attractive basis for selective targeting. Nadunolimab is designed to block IL-1 driven signaling and to enable immune-mediated killing through ADCC. Together, this supports an approach aimed not only at reducing disease burden, but at intervening closer to the drivers of the disease.
The target is also clinically relevant beyond mechanism alone.
IL1RAP has been associated with poorer survival in AML, supporting its relevance in more aggressive disease biology that links well to the PDAC program discussed earlier today, where IL1RAP was likewise associated with worse outcome and reinforces IL1RAP as a biologically and clinically meaningful target.
All in all, the early leukemia data and the broader biology strengthen the rationale for continued development of Nadunolimab in hematologic malignancies.
The Investigator-Initiated Trial at MD Anderson Cancer Center in Houston, supported by the US Department of Defense, has now completed Phase 1b and is progressing into Phase 2a; Nadunolimab in combination with Azacitidine or Azacitidine plus Venetoclax has shown an acceptable safety profile across cohorts, most notably in the high-risk MDS cohort. Five out of five evaluable patients achieved complete remission, with the sixth pending at the time of reporting. While these are still early days, the signals are clearly encouraging and confirmed. If confirmed in a larger cohort, could support advancing the hematological program of Cantargia. Next slide please. Beyond Nadunolimab, we are continuing to build the next phase of the platform through CAN14 and the broader CANxx engine. This reflects Cantargia's ambition to extend its IL1RAP expertise across a broader portfolio of next-generation therapeutics, supporting both long-term value creation and platform durability. CAN14 represents a bispecific inflammatory approach designed to build on IL1RAP biology while adding further functionality. While the ADC program represents an Oncology-directed approach aimed at selectively delivering cytotoxic payloads to IL1RAP-expressing tumors. Together, these programs broaden the potential reach of the platform across both inflammatory diseases and cancer.
CAN14 represents the platform expansion into inflammatory diseases through IL1RAP-based bispecific antibodies.
Together with CAN10, which is already advancing clinically, it helps validate our IL1RAP-driven approach beyond oncology. This bispecific strategy enables dual targeting for improved efficacy. It can help overcome pathway redundancy or resistance, and offers the potential to direct activity towards specific tissues. We see broad opportunity across dermatology, gastroenterology, respiratory disease, rheumatology, and systemic inflammatory conditions, and we expect to announce a second target for CAN14 by year-end 2026.
With that, I will now hand over to Patrik Renblad, who will take you through the financial results for the quarter.